233 related articles for article (PubMed ID: 24216509)
1. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.
Knelson EH; Gaviglio AL; Tewari AK; Armstrong MB; Mythreye K; Blobe GC
J Clin Invest; 2013 Nov; 123(11):4786-98. PubMed ID: 24216509
[TBL] [Abstract][Full Text] [Related]
2. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.
Knelson EH; Gaviglio AL; Nee JC; Starr MD; Nixon AB; Marcus SG; Blobe GC
J Clin Invest; 2014 Jul; 124(7):3016-31. PubMed ID: 24937430
[TBL] [Abstract][Full Text] [Related]
3. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
[TBL] [Abstract][Full Text] [Related]
4. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
[TBL] [Abstract][Full Text] [Related]
5. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
6. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
7. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
8. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
9. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
[TBL] [Abstract][Full Text] [Related]
10. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
11. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
12. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
Zhang S; Sun WY; Wu JJ; Gu YJ; Wei W
Oncol Rep; 2016 Apr; 35(4):2373-81. PubMed ID: 26882862
[TBL] [Abstract][Full Text] [Related]
14. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
17. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
Ikram F; Ackermann S; Kahlert Y; Volland R; Roels F; Engesser A; Hertwig F; Kocak H; Hero B; Dreidax D; Henrich KO; Berthold F; Nürnberg P; Westermann F; Fischer M
Mol Oncol; 2016 Feb; 10(2):344-59. PubMed ID: 26598443
[TBL] [Abstract][Full Text] [Related]
19. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
20. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
